drug · small molecule
VENCLEXTA
updated 6mo ago/ ve-NE-tə-klaks /
by $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 7- drugvenetoclax82 co-mentions · 22 sources
- tagApproval80 co-mentions · 20 sources
- tagSmall Molecule40 co-mentions · 20 sources
- tagOncology2 co-mentions · 2 sources
- tagHematology2 co-mentions · 1 sources
- companyInstitute of Hematology and Blood Diseases Hospital1 co-mentions · 1 sources
- tagAML1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for chronic lymphocytic leukemia and neoplasm and 38 investigational indications.
targets
Apoptosis regulator Bcl-2
all catalysts(0)
nothing on the calendar yet
Trials studying VENCLEXTA
- phase3A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- phase2Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- phase3A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
- phase3Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- phase1A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- phase2Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
- phase2Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- phase1Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
News(10)
- Sellas marks 9-month survival benefit in late-stage leukemia vaccine studySellas Life Sciences’ cancer vaccine for acute myeloid leukemia has passed a phase 3 test with a more than nine-month improvement in overall survival.fiercebiotech · 3d ago
- BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 dataBristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.fiercebiotech · 2mo ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 3mo ago
- Sarepta names former AbbVie R&D exec Michael Severino as next CEOAfter leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.biospace · 3mo ago
- Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersHundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…biopharma_dive · 6mo ago
- BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at VenclextaBeOne Medicines has clinched an accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie and Roche's Venclexta across a range of…endpoints · 6mo ago
- Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical PracticeSanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.onclive · 6mo ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 6mo ago
- FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell LymphomaThe FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.onclive · 6mo ago
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that